JP2018535432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535432A5 JP2018535432A5 JP2018536062A JP2018536062A JP2018535432A5 JP 2018535432 A5 JP2018535432 A5 JP 2018535432A5 JP 2018536062 A JP2018536062 A JP 2018536062A JP 2018536062 A JP2018536062 A JP 2018536062A JP 2018535432 A5 JP2018535432 A5 JP 2018535432A5
- Authority
- JP
- Japan
- Prior art keywords
- configuration
- ctc
- nuclear
- therapy
- nucleated cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233206P | 2015-09-25 | 2015-09-25 | |
| US62/233,206 | 2015-09-25 | ||
| PCT/US2016/053387 WO2017053763A2 (en) | 2015-09-25 | 2016-09-23 | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535432A JP2018535432A (ja) | 2018-11-29 |
| JP2018535432A5 true JP2018535432A5 (cg-RX-API-DMAC10.html) | 2019-10-31 |
| JP6936231B2 JP6936231B2 (ja) | 2021-09-15 |
Family
ID=58387342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536062A Active JP6936231B2 (ja) | 2015-09-25 | 2016-09-23 | 転移性去勢抵抗性前立腺癌（ｍＣＲＰＣ）患者における治療選択のためのバイオマーカーとしてのアンドロゲン受容体バリアント７ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190285636A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3353553B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6936231B2 (cg-RX-API-DMAC10.html) |
| CN (3) | CN118443943A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2016325617A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2999911A1 (cg-RX-API-DMAC10.html) |
| EA (1) | EA201890816A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL258318A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017053763A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101926117B1 (ko) * | 2017-08-18 | 2018-12-06 | 주식회사 싸이토젠 | 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법 |
| US20220184086A1 (en) * | 2019-03-28 | 2022-06-16 | Cardiff Oncology, Inc. | Plk1 inhibitors and psa levels in prostate cancer |
| CN112113821B (zh) * | 2020-05-28 | 2021-09-03 | 王剑 | 一种细胞病理学样本的多重染色制片方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014047285A1 (en) * | 2012-09-19 | 2014-03-27 | Paraskevi Giannakakou | Identifying taxane sensitivity in prostate cancer patients |
| EP3052940B1 (en) * | 2013-09-30 | 2021-05-26 | The Scripps Research Institute | Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients |
| WO2015112955A1 (en) * | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EA201691499A1 (ru) * | 2014-01-30 | 2017-02-28 | Эпик Сайенсиз, Инк. | Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям |
-
2016
- 2016-09-23 CA CA2999911A patent/CA2999911A1/en not_active Abandoned
- 2016-09-23 AU AU2016325617A patent/AU2016325617A1/en not_active Abandoned
- 2016-09-23 CN CN202410551103.0A patent/CN118443943A/zh active Pending
- 2016-09-23 JP JP2018536062A patent/JP6936231B2/ja active Active
- 2016-09-23 CN CN201680068025.2A patent/CN108450001A/zh active Pending
- 2016-09-23 WO PCT/US2016/053387 patent/WO2017053763A2/en not_active Ceased
- 2016-09-23 EA EA201890816A patent/EA201890816A1/ru unknown
- 2016-09-23 CN CN202410551097.9A patent/CN118443942A/zh active Pending
- 2016-09-23 US US15/762,076 patent/US20190285636A1/en not_active Abandoned
- 2016-09-23 EP EP16849728.7A patent/EP3353553B1/en active Active
-
2018
- 2018-03-22 IL IL258318A patent/IL258318A/en unknown
-
2023
- 2023-02-27 US US18/175,427 patent/US20240036047A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krol et al. | Detection of clustered circulating tumour cells in early breast cancer | |
| Maheswaran et al. | Circulating tumor cells: a window into cancer biology and metastasis | |
| Siravegna et al. | Integrating liquid biopsies into the management of cancer | |
| Schneck et al. | Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients | |
| Yap et al. | Circulating tumor cells: a multifunctional biomarker | |
| JP6912064B2 (ja) | 疾患の検出及び診断のための血液中の循環細胞バイオマーカーの使用並びにそれらを単離する方法 | |
| Li et al. | Molecular characterization of circulating tumor cells—from bench to bedside | |
| Mostert et al. | mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients | |
| Economopoulou et al. | Cancer of unknown primary origin in the genomic era: elucidating the dark box of cancer | |
| Schehr et al. | High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1 | |
| Shan et al. | Loss of stromal caveolin-1 expression: a novel tumor microenvironment biomarker that can predict poor clinical outcomes for pancreatic cancer | |
| JP7692075B2 (ja) | 循環細胞を用いて被検者における治療反応及び疾患の進行をモニターする方法 | |
| JP2019502384A5 (cg-RX-API-DMAC10.html) | ||
| JP2020522697A5 (cg-RX-API-DMAC10.html) | ||
| Bernardes et al. | EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study | |
| Nolan et al. | Detection of apoptotic circulating tumor cells using in vivo fluorescence flow cytometry | |
| Halilovic et al. | HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study | |
| Rink et al. | The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder | |
| Bou Zerdan et al. | Liquid biopsies and minimal residual disease in lymphoid malignancies | |
| Hugen et al. | Circulating tumor cells in genitourinary malignancies: an evolving path to precision medicine | |
| Wouters et al. | Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design | |
| Miyamoto et al. | Cell-free and circulating tumor cell–based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine? | |
| Wu et al. | Multiparameter evaluation of the heterogeneity of circulating tumor cells using integrated RNA in situ hybridization and immunocytochemical analysis | |
| Fischer | Circulating tumor cells: seeing is believing | |
| Harris et al. | Quest for the ideal cancer biomarker: an update on progress in capture and characterization of circulating tumor cells |